Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue
OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc("Tetra" or the Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that itfiled a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.
- OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc("Tetra" or the Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that itfiled a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.
- GRAS status will allow for the broad application of this novel ingredient in foods as well as dietary supplements.
- Research conducted through Tetra has shown that cannabis plant residue can increase the growth of beneficial gut microbes including bothLactobaccillus rhamnosusandBifidobacterium longum.
- If granted, this patent application will provide Tetra with protection for the use of cannabis plant residue material containing residual cannabinoids within a specified profile range, as an oral prebiotic component alone or in combination with other pro, post, para, or prebiotics as a dietary supplement for gastrointestinal health.